Our lab is interested in understanding the biological fate of nanomedicines and biological products to facilitate the development of next-generation medicines. We use cutting-edge analytical technologies to develop models of particle interaction with proteins. Interdisciplinary ways of working sit at the heart of what we do.
We are also interested in understanding the biology of cancer with a specific focus on nuclear import and DNA repair. Through a better characterization of timescales of DNA repair factor recruitment and the elucidating the role of nuclear import, we can develop new drugs for untreatable cancers.
When we are not in the lab and doing science, we are passionate about making our science accessible to the classroom.
If you would be interested in joining our lab for an internship or would like to join us as a PhD candidate, please do not hesitate to contact me!
Publications
Nicholas J. W. Rattray, Drupad K. Trivedi, Yun Xu, Tarani Chandola, Caroline H. Johnson, Alan D. Marshall, Krisztina Mekli, Zahra Rattray, Gindo Tampubolon, Bram Vanhoutte, Iain R. White, Frederick C. W. Wu, Neil Pendleton, James Nazroo, Royston Goodacre
Nature Communications, vol. 10(1), 2019 Nov 1
Evaluation of temporal aggregation processes using spatial intensity distribution analysis
Zahra Rattray, Egor Zindy, Karen M. Buzza, Alain Pluen
2019 Aug 23, pp. 141-155
Zahra Rattray, Jaymin M. Patel, Phillip W. Noble, Valentina Dubljevic, Deanne L. Greenwood, James A. Campbell, James E. Hansen
Cancer Research, vol. 78, 2018 Jun 1, pp. 2773-2773
Compositions and methods for enhancing nuclear translocation
Zahra Rattray, James E. Hansen
2018 Jan 1
View all
Projects
Evaluation of protein corona formation on nanomedicines
Our team uses particle metrology techniques in combination with proteomics analysis to better understand how nanomedicines interact with biologically-relevant media. This can support the development of future therapies relying on drug delivery.
Courses
I teach on various modules in the MPharm degree programme such as Bench to Bedside which considers the drug development process.